About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD0.37
- USD0.38
- USD0.36
- USD4.02
- -24.00%
- 11M
- 147.43k
- 836.79k
- 20M
- 0.24
- -85.50%
Stock News
3 hours ago
FedEx is the latest company to sound the alarm on the U.S. economy
MarketWatch
4 hours ago
The 10 most expensive places in the U.S. to start a new business, report finds
CNBC
5 hours ago
We're adding a well-known tech stock to our Bullpen watchlist after Nvidia's big AI event
CNBC
7 hours ago
Here's what Cramer hopes to learn about Home Depot at its meeting for managers
CNBC
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
